Nkarta Inc
NKTX2.000USD
+0.010+0.50%
收盘 09/19, 16:00（美东）报价延迟15分钟
142.05M总市值
亏损市盈率 TTM
关于 Nkarta Inc 公司
Nkarta, Inc. 是一家临床阶段的生物制药公司，致力于开发同种异体、现成的工程化自然杀伤 (NK) 细胞疗法，用于治疗患有自身免疫性疾病或血液系统恶性肿瘤的患者。该公司正在开发 NKX019，一种针对 CD19 抗原的嵌合抗原受体-自然杀伤 (CAR NK) 候选产品和 NKX101，一种针对展示 NKG2D 配体的细胞的 CAR NK 候选产品。这两种候选产品均支持按需、现成的方法，包括规模化生产以扩大患者的使用范围。其 NKX019 自身免疫计划基于消除产生自身抗体的病理性 B 细胞的潜力。其 NKX019 肿瘤学计划基于通过靶向可靠表达在这些类型的癌细胞上的 CD19 抗原来治疗多种 B 细胞恶性肿瘤的潜力。其 NKX101 项目旨在增强先天 NK 细胞生物学检测和杀死癌细胞的能力。
公司简介
公司代码NKTX
公司名称Nkarta Inc
上市日期Jul 10, 2020
CEOMr. Paul J. Hastings
员工数量157
证券类型Ordinary Share
年结日Jul 10
公司地址1150 Veterans Boulevard
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94080
电话19254071049
网址https://www.nkartatx.com/
公司代码NKTX
上市日期Jul 10, 2020
CEOMr. Paul J. Hastings
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Paul J. Hastings
Mr. Paul J. Hastings
Chief Executive Officer, Director
Chief Executive Officer, Director
107.34K
-1.64%
Dr. Shawn Rose
Dr. Shawn Rose
Chief Medical Officer and Head of Research and Development
Chief Medical Officer and Head of Research and Development
--
--
Dr. Nadir Mahmood, Ph.D.
Dr. Nadir Mahmood, Ph.D.
President, Principal Financial Officer
President, Principal Financial Officer
--
--
Dr. George Vratsanos
Dr. George Vratsanos
Independent Director
Independent Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Simeon J. George, M.D.
Dr. Simeon J. George, M.D.
Independent Director
Independent Director
--
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Independent Director
Independent Director
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
Ms. Angela Thedinga
Ms. Angela Thedinga
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Paul J. Hastings
Mr. Paul J. Hastings
Chief Executive Officer, Director
Chief Executive Officer, Director
107.34K
-1.64%
Dr. Shawn Rose
Dr. Shawn Rose
Chief Medical Officer and Head of Research and Development
Chief Medical Officer and Head of Research and Development
--
--
Dr. Nadir Mahmood, Ph.D.
Dr. Nadir Mahmood, Ph.D.
President, Principal Financial Officer
President, Principal Financial Officer
--
--
Dr. George Vratsanos
Dr. George Vratsanos
Independent Director
Independent Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Simeon J. George, M.D.
Dr. Simeon J. George, M.D.
Independent Director
Independent Director
--
--
收入明细
FY2020
FY2019
FY2018
暂无数据
地区USD
名称
营收
占比
United States
0.00
0.00%
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
RA Capital Management, LP
15.21%
Tang Capital Management, LLC
9.93%
Samsara BioCapital, LLC
5.31%
BlackRock Institutional Trust Company, N.A.
5.15%
New Enterprise Associates (NEA)
5.02%
其他
59.38%
持股股东
持股股东
占比
RA Capital Management, LP
15.21%
Tang Capital Management, LLC
9.93%
Samsara BioCapital, LLC
5.31%
BlackRock Institutional Trust Company, N.A.
5.15%
New Enterprise Associates (NEA)
5.02%
其他
59.38%
股东类型
持股股东
占比
Venture Capital
34.23%
Hedge Fund
20.86%
Investment Advisor
15.65%
Investment Advisor/Hedge Fund
13.02%
Corporation
4.45%
Research Firm
2.48%
Individual Investor
0.94%
Family Office
0.12%
Bank and Trust
0.09%
其他
8.15%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
285
69.55M
98.01%
-21.71M
2025Q1
300
69.02M
97.27%
-22.80M
2024Q4
316
69.51M
100.26%
-10.53M
2024Q3
335
73.98M
106.61%
-9.96M
2024Q2
333
73.31M
105.81%
-2.74M
2024Q1
329
70.79M
102.89%
+13.14M
2023Q4
312
47.25M
96.07%
-11.76M
2023Q3
310
42.86M
87.43%
-15.68M
2023Q2
313
46.09M
94.31%
-14.43M
2023Q1
320
48.07M
98.40%
-11.00M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RA Capital Management, LP
10.81M
15.23%
--
--
Mar 31, 2025
Tang Capital Management, LLC
7.06M
9.94%
+41.48K
+0.59%
Mar 31, 2025
Samsara BioCapital, LLC
3.77M
5.31%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.01M
5.65%
-73.17K
-1.79%
Mar 31, 2025
New Enterprise Associates (NEA)
3.57M
5.03%
--
--
Mar 31, 2025
SR One Capital Management, LP
3.33M
4.7%
--
--
Apr 10, 2025
Citadel Advisors LLC
3.51M
4.94%
-56.08K
-1.57%
Mar 31, 2025
GSK plc
3.16M
4.46%
+3.16M
--
Mar 27, 2024
EQT Life Sciences
2.84M
4%
--
--
Feb 12, 2025
The Vanguard Group, Inc.
2.53M
3.56%
-5.67K
-0.22%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
JPMorgan Fundamental Data Science Small Core ETF
0.05%
iShares Micro-Cap ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Russell 2000 Value ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
查看更多
JPMorgan Fundamental Data Science Small Core ETF
占比0.05%
iShares Micro-Cap ETF
占比0.03%
ProShares Ultra Nasdaq Biotechnology
占比0.02%
iShares Russell 2000 Value ETF
占比0.01%
Avantis US Small Cap Equity ETF
占比0.01%
iShares Biotechnology ETF
占比0.01%
Invesco Nasdaq Biotechnology ETF
占比0.01%
Invesco RAFI US 1500 Small-Mid ETF
占比0.01%
ProShares UltraPro Russell2000
占比0%
ProShares Hedge Replication ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
